What are the prospects for the Adalimumab biosimilar pipeline in dermatology
In recent years, the evolving landscape of biosimilars has helped flood the market with a huge amount of information. In dermatology, biosimilars approvals have been pending since 2016 for adalimumab, a tumor necrosis factor inhibitor used to treat moderate to severe plaque psoriasis and hidradenitis suppurativa (HS); however, the former was only recently launched. Adalimumab-atto … Read more